companiesCompany
Atara Biotherapeutics
aka Atara Biotherapeutics, Inc., NASDAQ:ATRA
Atara Biotherapeutics is the Californian company behind Ebvallo, the first approved off-the-shelf T-cell therapy, which treats Epstein-Barr virus lymphoma after transplant using T cells from healthy donors.
Overview
Atara Biotherapeutics develops allogeneic Epstein-Barr virus-specific T-cell therapies. Tabelecleucel (Ebvallo), made from banked donor T cells matched by HLA, was approved in the European Union in December 2022 and by the FDA in 2025 for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease; Pierre Fabre holds worldwide commercial rights. Atara's EBV-targeted CAR-T programme ATA3219 for lymphoma and lupus was paused in 2025 as the company restructured.
Headquarters
Thousand Oaks, California, US
Scorecard
All companies#245of 1181 companies, score 16
- approved products +6
- modalities +2
- regions +1
- registry trials +7
1 approved, 0 in phase 3, 0 earlier, 0 targets, 11 registry studies. Formula on the scorecards page.
Type
cell therapy · NASDAQ:ATRA
Stage
Public
Website
Founded
2012